On May 29, 2024, David Weill, Director at TransMedics Group Inc (NASDAQ:TMDX), executed a sale of 1,193 shares of the company.
For us, stock picking is in large part the hunt for the truly magnificent stocks. Mistakes are inevitable, but a single...
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on May 14, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 18,320 shares of its common stock and an aggregate of 12,068 restricted stock units to 8 employees, each as a material inducement for each employee's entry into employment with TransMedics. The g